Semax Half-Life: What Stability Studies Can and Cannot Tell Us
Direct answer: A well-validated human plasma terminal half-life for Semax is not established in the accessible peer-reviewed sources cited here. Published work describes enzymatic proteolysis and stability in selected biological media, but those experiments should not be converted into a universal human half-life.
Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, often written MEHFPGP. It combines the ACTH(4–7) sequence with a Pro-Gly-Pro extension. The Semax and ACTH-fragment guide explains why Semax is a distinct peptide record rather than a synonym for every ACTH fragment.
What evidence exists?
A proteolysis study indexed by NIH PubMed (PMID 22096989) compared Semax with N-terminal analogues using aminopeptidases. It identified shorter products, including the pentapeptide His-Phe-Pro-Gly-Pro, and showed that changing the N-terminal residue altered degradation rate. This is mechanistic enzyme-system evidence, not a human pharmacokinetic curve.
A second paper indexed by NIH PubMed (PMID 23652441) examined an acetylated Semax analogue in biological media. That analogue is not the same molecular form as unmodified Semax, so its stability cannot be assigned directly to MEHFPGP.
| Evidence type | What it measures | Why it is not a universal human half-life |
|---|---|---|
| Purified aminopeptidase experiment | Susceptibility and degradation products under defined enzyme conditions | Lacks whole-body distribution and clearance |
| Biological-media stability test | Parent loss or fragment formation in a selected matrix | Matrix and molecular form may differ |
| Tissue-membrane experiment | Interaction or degradation in a tissue preparation | Not a systemic plasma concentration-time study |
| Human terminal pharmacokinetic study | Timed quantitative concentrations and terminal slope | This is the evidence needed for a human half-life claim |
Stability, degradation rate, and half-life are different records
“Stable for a period” can mean that a parent-peptide signal remained above a threshold in a specific assay. An enzymatic degradation rate describes an experimental system. Terminal pharmacokinetic half-life describes concentration decline in a living organism after absorption and distribution. The terms answer different questions.
Semax fragment profiles also matter. If an assay measures only total immunoreactivity, it may not distinguish intact MEHFPGP from related fragments. Sequence-selective LC-MS methods can narrow that uncertainty, but recovery, calibration, and limits of quantitation still need reporting. The Semax stability guide explains why an intact-parent signal should be separated from a fragment profile.
What would a stronger Semax half-life study report?
A useful study would identify the exact molecular form and salt, biological matrix, species and population, route, formulation, sampling schedule, extraction recovery, parent-selective assay, metabolite or fragment handling, and model used to estimate the terminal slope. It would also report uncertainty rather than only one rounded number.
Regulatory risk reviews and formulation assessments answer different questions from a pharmacokinetic study. They should not be read as approval records or as measured human half-lives unless they actually report timed, quantitative parent-peptide data.
For material documentation, the Semax research material page identifies the catalog entry and the COA library supports lot matching. Related records appear in the Peptide Bioregulators collection. These pages do not establish biological disposition.
The Semax animal-study guide helps keep time points and endpoints attached to their original models, while the Semax transcriptome guide separates gene-expression observations from pharmacokinetic measurements.
Research limitations
Much of the Semax literature uses enzyme systems, animal tissues, nonhuman models, or analogues. Some publications are available only as brief English abstracts. These constraints limit conclusions about intact-parent exposure in humans. A precise half-life should remain “not established” unless a source reports validated, timed, parent-selective human measurements.
Frequently asked questions
What is the human half-life of Semax?
The cited accessible literature does not establish a validated human terminal plasma half-life for intact Semax.
Do enzyme-degradation experiments provide a half-life?
They can provide an experimental degradation rate under their stated conditions, but not a universal whole-body half-life.
Can data for acetylated Semax be applied to Semax?
Not automatically. Acetylation changes molecular identity and can change proteolytic stability.
Why must fragments be measured separately?
Because a fragment signal can remain after the intact parent peptide has declined, and the two signals answer different questions.
NEXTWAVE PEPTIDES treats uncertainty as part of the research record rather than filling missing evidence with an unsupported number.